Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 6/20 | 0.53 |
| ▸ | CHRNG | P07510 | 6/20 | 0.53 |
| ▸ | CHRNB1 | P11230 | 6/20 | 0.53 |
| ▸ | CHRND | Q07001 | 6/20 | 0.53 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7047071 | 0.93 | GRIA1 (0.54) | CHRNA1CHRNGCHRNB1CHRNDGRIA1 | |
| SCHEMBL4650266 | 0.90 | GRIA1 (0.49) | CHRNA1CHRNGCHRNB1CHRNDGRIA1 | |
| SCHEMBL4651088 | 0.86 | MAPT (0.43) | PTPN1 | |
| SCHEMBL7054281 | 0.86 | CHRNB2 (0.49) | GRIA1CTSL | |
| SCHEMBL4650233 | 0.85 | ITGB3 (0.48) | — | |
| SCHEMBL4651118 | 0.85 | ITGB3 (0.42) | GRIA1PTPN1 | |
| SCHEMBL7048812 | 0.82 | THRB (0.48) | TRPV1 | |
| SCHEMBL4650264 | 0.82 | NPY5R (0.52) | — | |
| SCHEMBL4650967 | 0.81 | ITGB3 (0.44) | — | |
| SCHEMBL4650222 | 0.80 | ITGB3 (0.53) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6586467-B2 | Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus | ARRAY BIOPHARMA INC. | 2003-07-01 | — | — | US | claimed |
| EP-1301474-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | Array Biopharma Inc. (US) | 2003-04-16 | — | — | EP | claimed |
| US-20020040003-A1 | Preparation of phosphatase inhibitors | ARRAY BIOPHARMA INC. | 2002-04-04 | — | — | US | claimed |
| WO-2002004412-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2002-01-17 | — | — | WO | claimed |
| US-6586467-B2 | Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus | ARRAY BIOPHARMA INC. | 2003-07-01 | — | — | US | disclosed |
| EP-1301474-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | Array Biopharma Inc. (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20020040003-A1 | Preparation of phosphatase inhibitors | ARRAY BIOPHARMA INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002004412-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040003-A1 | Preparation of phosphatase inhibitors | PTPRS, PTPRO, PTPRR | CHRNA1 3911/4885CHRNG 4681/4885CHRNB1 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.